- Home
- CGEN vs XGN Comparison
CGEN vs XGN Comparison
Compare CGEN & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- XGN
- Stock Information
- Founded
- CGEN 1993
- XGN 2002
- Country
- CGEN Israel
- XGN United States
- Employees
- CGEN N/A
- XGN N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- XGN Medical Specialities
- Sector
- CGEN Health Care
- XGN Health Care
- Exchange
- CGEN Nasdaq
- XGN Nasdaq
- Market Cap
- CGEN 167.4M
- XGN 138.3M
- IPO Year
- CGEN 2000
- XGN 2019
- Fundamental
- Price
- CGEN $1.45
- XGN $9.81
- Analyst Decision
- CGEN
- XGN Strong Buy
- Analyst Count
- CGEN 0
- XGN 4
- Target Price
- CGEN N/A
- XGN $11.75
- AVG Volume (30 Days)
- CGEN 206.7K
- XGN 211.3K
- Earning Date
- CGEN 08-06-2025
- XGN 07-29-2025
- Dividend Yield
- CGEN N/A
- XGN N/A
- EPS Growth
- CGEN N/A
- XGN N/A
- EPS
- CGEN N/A
- XGN N/A
- Revenue
- CGEN $22,144,000.00
- XGN $58,862,000.00
- Revenue This Year
- CGEN N/A
- XGN $22.09
- Revenue Next Year
- CGEN $159.40
- XGN $13.62
- P/E Ratio
- CGEN N/A
- XGN N/A
- Revenue Growth
- CGEN N/A
- XGN 3.89
- 52 Week Low
- CGEN $1.13
- XGN $2.38
- 52 Week High
- CGEN $2.66
- XGN $10.34
- Technical
- Relative Strength Index (RSI)
- CGEN 48.38
- XGN 60.98
- Support Level
- CGEN $1.39
- XGN $9.48
- Resistance Level
- CGEN $1.46
- XGN $10.34
- Average True Range (ATR)
- CGEN 0.06
- XGN 0.40
- MACD
- CGEN 0.00
- XGN -0.09
- Stochastic Oscillator
- CGEN 52.63
- XGN 44.21
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.